Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MDM2 C464A |
| Therapy | YF438 |
| Indication/Tumor Type | triple-receptor negative breast cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MDM2 C464A | triple-receptor negative breast cancer | no benefit | YF438 | Preclinical - Cell culture | Actionable | In a preclinical study, YF438 treatment did not inhibit cell growth or induce apoptosis in triple-negative breast cancer cells expressing MDM2 C464A in culture (PMID: 33985974). | 33985974 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33985974) | Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer. | Full reference... |